natgillin/translations-raw huggingface dataset:
a pair of nucleic acid primers capable of specifically amplifying at least one 16S rDNA sequence selected from the list consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and SEQ ID NO:10; and 
par nukleinskokiselinskih početnica koje mogu specifično amplificirati najmanje jedan 16S rDNA slijed kojeg se bira iz spiska kojeg čine SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 i SEQ ID NO:10; i
The second rows of knitting 2 are composed of at least one yarn 2a made of coated elastomer (for example Elastane), preferably a double-coated elastomer yarn 2a. 
Parni redovi pletiva 2 su izrađeni od najmanje jednog konca 2a izrađenog od prevučenog elastomera (na primjer Elastana), ponajprije dvostruko prevučenog elastomernog konca 2a.
The siRNA according to any one of claims 1 to 5, wherein a nucleotide is a nucleotide analog having chemically modified sugar, base, and/or phosphate. 
SIRNA u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da je nukleotid analog nukleotida koji ima kemijski sastav modificiranog šećera, baze 1 / ili fosfata.
Mould system according to claim 9, wherein each layer of strips (15) comprise at least two strips which extend in the extension of one another, each of said two strips being mutually coupled. 
Sustav kalupa u skladu s patentnim zahtjevom 9, pri čemu svaki sloj traka (15) obuhvaća najmanje dvije trake koje se produžuju u nastavku jedna na drugu, svaka od navedenih dviju traka je međusobno povezana,
Thereby in maximum 5 parts by weight of waste-PET may be incorporated into 95 parts by weight of “virgin”-PET, to avoid adversely effecting the quality of the respective product. 
Na taj se način može maksimalno ugraditi 5 težinskih dijelova otpadnog PET-a u 95 težinskih dijelova «djevičanskog» PET-a, kako se ne bi utjecalo na kvalitetu dotičnog proizvoda.
a single bond, and wherein the asterisk indicates the point of attachment to (Y)y; and the wavy line indicates the point of attachment to L2. 
' 5 u kojima zvjezdica pokazuje mjesto vezanja za (Y),; te valovita linija pokazuje mjesto vezanja za L.
The method of manufacturing of claim 17 wherein a preservative is added to the at least one oily vehicle in a). 
Postupak proizvodnje prema patentnom zahtjevu 9 naznačen time što se konzervans dodaje u uljasti nosač u koraku a).
The combined organic layers were washed with water (5 mL x 2) followed by saturated aqueous NaCl (5 mL x 2). 
Spojeni organski slojevi isprani su sa vodom (5 mL x 2) nakon čega je uslijedila zasićena vodena otopina NaCI (5 mL x 2).
The method of claim 10, further comprising the step of: e2) further filtration of the filtered fluid obtained in step d) or e1) with a third filter with a smaller pore size than that of the second filter, wherein the pore size of the third filter is in the range 0.3 um to 10 um. 
Postupak prema bilo kojem od zahtjeva 1 do 10, dodatno obuhvaća korak: e2) dodatno filtriranje filtrirane tekućine dobivene u koraku d) ili e1) upotrebom trećeg filtra koji ima manju veličinu pora od drugog filtra, pri čemu je veličina pora trećeg filtra u rasponu od 0.3 do µm do 10 µm.
Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent applications referenced in this application are hereby incorporated by reference in their entirety into the present disclosure. 
Kroz ovu prijavu, različite publikacije, patente i objavljene patentne prijave su navođene da bi se potpuno opisao i objasnio izum i stanje tehnike kojem izum pripada.
The liquefied gas treatment method according to claim 1, wherein the compressor (150;13) includes a plurality of compression cylinders (14), and the BOG generated in the cargo tank is compressed by a part of the plurality of compression cylinders and is supplied as fuel to the sub engine. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13,13b). Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 5, naznačen time što motor (3) uključuje MEGI motor i DF motor.
The process of clause 1, wherein the Lewis acid is selected from the group consisting of zinc chloride, zinc bromide, ferric chloride, and ferric bromide. 
Postupak prema patentnom zahtjevu 1, gdje je Lewis-ova kiselina izabrana iz grupe koju čine cinkov klorid, cinkov bromid, želljezni (III) klorid i željezni (IID) bromid.
A compound for use in reducing the symptoms of muscular dystrophy, wherein said compound has structural Formula I: or a salt thereof, wherein: 
Spoj VBP15 ili VBP6 za uporabu u liječenju simptoma mišićne distrofije, pri čemu su navedeni spojevi VBP15 ili VBP6 strukturnih formula:
represents an optionally substituted C1-6 alkylene group, an optionally substituted C2-6 alkenylene group or an optionally substituted C2-6 alkynylene group; 
supstituenti za C1-6 alkilensku skupinu, C2-6 alkenilen skupinu i C2-6 alkinilen skupinu od X1 su jedna ili više skupina odabranih iz skupine supstituenata B;
represents hydrogen, (C1-C3)alkyl or 2-methoxy-ethyl; or R2 and R3 form, together with the nitrogen that carries them, a ring of 5 to 7 members, which ring is substituted with amino-(C1-C4)alkyl; 
predstavlja vodik, (C1-C3)alkil ili 2-metoksi-etil; ili i R3zajedno s dušikom koji ih nosi, tvore prsten od 5 do 7 člana, a taj prsten je supstituiran s amino-(C1-C4)alkilom;
or a N-oxide, or a pharmaceutically acceptable salt thereof. 
ili N-oksid, ili njegova farmaceutski prihvatljiva sol ili njegov solvat.
A key intermediate of the route described in WO2009/090251 is a compound of formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group. 
(1) gdje je RI vodikova ili dušikova zaštitna grupa; spomenuti postupak sadrži sljedeće korake: (1) priprema spoja sa formulom (4), ili njegove soli, a
contacting the antigen presenting cells of step (iii) with T-cells to evaluate the ability of the peptide to stimulate the T-cells; and 
stavljanja u kontakt predočnih stanica iz koraka (iii) s T-stanicom kako bi se procijenilo sposobnost peptida da stimulira T-stanice; i
Preferred cellulose derivatives are hydroxypropylmethyl cellulose and/or hydroxypropyl cellulose. 
Poželjnji celulozni derivati su hidroksipropilmetilceluloza i(li) hidroksipropilceluloza.
“X” and “n” include alkylene spacers which may contain ether or amino functionalities. 
eterske ili amino funkcionalne grupe.,,P" može obuhvaćati odgovarajuću zaštitnu grupu.
Specifically, the aqueous pharmaceutical formulation can comprise 90 µg/mL zinc, 2.7 mg/mL m-cresol and 20 mg/ml glycerol 85%. 
Vodena formulacija u skladu s patentnim zahtjevom 6, naznačena time što sadrži 90 mg/ml cinka, 2,7 mg/ml m- krezola i 20 mg/ml 85%-tnog glicerola.
for a compound of Formula I where X is O, coupling a corresponding compound having the formula II with a corresponding compound having the formula VII in the presence of a base; or 
(D) zaspoj s formulom I gdje X je O, sparivanje odgovarajućeg spoja koji ima formulu HI u prisutnosti baze; ili
The wet granulated pharmaceutical composition according to one or more of the preceding claims 1 to 5, wherein said surfactant or combination of surfactants is present in a range of concentrations between about 0.1 and 10 % (w:w) of said composition, preferably in the range between 0.5 to 5 % (w:w) of said composition. 
Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što je navedena kombinacija surfaktanata prisutna u rasponu koncentracija od otprilike 0,1% do 10 % (tož./tcž.) navedenog pripravka, po mogućnosti u rasponu od 0,5% do 5 % (tež./tež.) navedenog pripravka.
In the vicinity of the introduction end, cylinder 4 is provided with a sampling opening 6 and a number of spray openings 7 (cf. also Figure 2). 
U blizini kraja koji se uvodi, cilindar 4 je snabdjeven s otvorom za uzimanje uzorka 6 i većim brojem otvora za prskanje 7 (usporedi također sliku 2).
A compound of formula (3): 
Sinteza međuprodukata formule (3):
The pharmaceutical composition according to claim 10, further comprising at least one additional therapeutic agent. 
Farmaceutski sastav prema patentnom zahtjevu 21, naznačen time, da nadalje sadrži barem jednu dodatnu terapeutski djelotvornu tvar.
), skin protectants or conditioners, humectants, ultraviolet radiation absorbers, sunless tanning agents and the like, anti-oxidants, anti-aging agents, skin lightening agents, and insect repellants, depending on the intended uses for the formulations. 
), protektivi za kožu ili rcgencratori, ovlaživači, sredstva za apsorpciju ultraljubičastog zračenja, sredstva za tamnjenje bez sunca i slično, antioksidansi, sredstva protiv starenja, sredstva za posvjetljivanje kože, i sredstvo za odbijanje kukaca, ovisno o predviđenim upotrebama pripravaka.
It is known that tumor cells circulate in the bloodstream of many individual humans (as well as other vertebrate animals), even for tumors that are considered solid, unitary tumors, such as ovarian, prostate, and breast cancers. 
Postupak za koji se traži zaštita u jednom od patentnih zahtjeva 21 do 24, pri čemu je najmanje jedna cirkulirajuća stanica tumora izvedena iz čvrstog tumora kao što je tumor jajnika, prostate, ili tumor karcinoma dojke.
A process according to any one of the preceding claims, characterized in that the content of the at least one flocculating additive A in the first aqueous suspension S1 is from 0.001 to 20 wt.-%, more preferably from 0.5 to 10 wt.-%, and most preferably from 3 to 5 wt.-%, based on the total weight of the first aqueous suspension S1, and/or the content of the at least one flocculating additive B in the second aqueous suspension S2 is from 0.001 to 20 wt.-%, more preferably from 0.1 to 10 wt.-%, and most preferably from 0.2 to 0.8 wt.-%, based on the total weight of the second aqueous suspension S2. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se sadržaj najmanje jednog flokulirajućeg aditiva A u prvoj vodenoj suspenziji S1 kreće od 0,001 do 20 %, težinski, poželjnije se kreće od 0,5 do 10 %, težinski, a najpoželjnije od 3 do 5 %, težinski, na osnovi ukupne težine prve vodene suspenzije S1, i/ili se sadržaj najmanje jednog flokulirajućeg aditiva B u drugoj vodenoj suspenziji 52 kreće od 0,001 do 20 %, težinski, poželjnije se kreće od 0,1 do 10 %, težinski, a najpoželjnije od 0,2 do 0,8 %, težinski, na osnovi ukupne težine druge vodene suspenzije S2.
Preferably a monocyclic heterocyclyl has between 5 and 7 ring atoms, or between 5 and 6 ring atoms; there may be between 1 and 5 heteroatoms or heteroatom moieties in the ring, and preferably there are between 1 and 3, or between 1 and 2, or there may be 1 heteroatom or heteroatom moiety. 
Preferira se da monociklički heterociklički radikal ima od 5 do 7 atoma u prstenu, ili od 5 do 6 atoma u prstenu; može biti od 1 do 5 heteroatoma ili heteroatomskih jedinica u prstenu, a preferira se da bude od 1 do 3, ili od 1 do 2, ili može biti 1 heteroatom ili heteroatomska jedinica.
General Description The first step of Scheme A involves the condensation/cyclisation of the amide compound of formula 1 with a substituted aniline compound in the presence of phosphorus trichloride to obtain the 7-nitro substituted quinazolin-4-one compound of formula 2. 
ž Opći opis Prvi stupanj u shemi A uključuje kondenzaciju/ ciklizaciju amidnog spoja formule 1 sa supstituiranim anilinskim spojem u prisutnosti fosfornog triklorida, čime se dobije 7-nitro supstituirani kinazolin-4-on, spoj formule 2.
extracting the constellation values corresponding to Layer 1 signaling data from the frequency-deinterleaved constellation values corresponding to Layer 1 signaling data and Layer 1 header; 
izlučivanje konstelacijskih vrijednosti koje odgovaraju signalnom podatku L1 iz konstelacijskih vrijednosti raspletenog vremena koje odgovaraju signalnom podatku L1 i zaglavlju razine 1;
The antibody or antigen binding portion thereof of claim 1, wherein the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 7, the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 8, the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 9, the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 10, the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 11, and the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 12. 
Protutijelo ili njegov dio za vezanje na antigen u skladu s patentnim zahtjevom 1, naznačeno time, da teški lanac CDR1 sadrži aminokiselinski odsječak SEQ ID NO: 7, teški lanac CDR2 sadrži aminokiselinski odsječak SEQ ID NO: 8, teški lanac CDR3 sadrži aminokiselinski odsječak SEQ ID NO: 9, laki lanac CDR1 sadrži aminokiselinski odsječak SEQ ID NO: 10, laki lanac CDR2 sadrži aminokiselinski odsječak SEQ ID NO: 11 te laki lanac CDR3 sadrži aminokiselinski odsječak SEQ ID NO: 12.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, or a cell according to claim 6, in solution or in lyophilized form; and 
Komplet koji sadrži posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku.
filling said micro trench with filling material after said plurality of arranged ducts/cables have been successively routed; and sealing said micro trench with sealing material so as to restore said surface layer. 
- punjenja svih navedenih mikro-rovova na odgovarajuću razinu s odgovarajućim materijalom za punjenje nakon što su navedeni pluralitet kanala / kabela usmjereni do njihovih navedenih krajnjih točaka; - -brtvljenja navedenog mikro-rova odgovarajućim materijalom za brtvljenje.
Effervescent tablet according to claim 1, wherein said active principle is selected from corticosteroids and mucolytic agents. 
Šumeća tableta u skladu s patentnim zahtjevom 1, naznačena time što se navedena aktivna tvar bira između kortikosteroida i mukolitika.
A compound according to claim 16, or pharmaceutically acceptable salt thereof wherein the disease caused by amyloid-B is Alzheimer's disease, senile dementia, Down's syndrome or amyloidosis. 
Spoj u skladu s patentnim zahtjevom 16, ili njegova farmakološki prihvatljiva sol, naznačen time, da je bolest prouzročena beta-amiloidom Alzheimerova bolest, senilna demencija, Downov sindrom ili amiloidoza.
An isolated nucleic acid encoding the humanized antibody of Claim 1. 
Izolirana nukleinska kiselina naznačena time da kodira humanizirano protutijelo prema zahtjevu 1.
The results have been summarized in the FIG. 2 . 
Rezultati su sumirani na slici 2.
The method of claim 22, wherein replacing at least a portion of the solubilizing component with an exchange solvent is done by adding the exchange solvent to the inside of the containment vessel. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što se sastoji u zamjeni u najmanju ruku dijela solubilizirajuće komponente zamjenskim otapalom dodavanjem zamjenskog otapala u unutrašnji dio posude za držanje.
The pharmaceutical composition according to claim 8, wherein the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), or imiquimod or resimiquimod. 
Farmaceutski sastav prema zahtjevu 5, gdje je adjuvans odabran iz skupine koja sadrži čimbenike za poticanje kolonija kao što su čimbenik za poticanje granulocitnih i makrofagnih kolonija (GM-CSF), odnosno imikvimod ili resikvimod.
The composition of claim 1, wherein said regulatory RNA targets the RNA transcript encoding a protein that contributes to drug resistance, apoptosis resistance or neoplasticity. 
Pripravak prema zahtjevu 1, gdje ta regulatorna RNA cilja RNA transkript koji kodira protein koji doprinosi otpornosti na lijekove, otpornosti na apoptozu ili neoplastičnosti.
A conjugate according to claim 5, having a structure represented by formula (II-1'): where R6 is Me or n-Pr and Ab is an antibody that preferably is an anti-CD70, anti-mesothelin, or anti-glypican 3 antibody. 
o . SU S Prco gdje R" je Meili n-Pri Ab je daa koje je poželjno anti-CD70, anti-mezotelin, ili anti-glipikan 3 antitijelo.
Fab fragment which is a monomeric fragment comprising the entire L chain, and a VH-CH1 fragment of the H chain, bound together through a disulfide bond; 
Fab fragment koji je monomerni fragment koji sadrži cijeli L lanac i VH-CHI1 fragment H lanca, vezane zajedno preko disulfidne veze;
Heinrich Bruning discovered that normally soluble metal salts could be made insoluble, or fixed inside wood, by addition of large amounts of chromium. 
Heinrich Bruning je otkrio da se normalno topljive metalne soli mogu učiniti netopljivima, ili fiksirati unutar drva, dodatkom velikih količina kroma.
N-[4-(3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide, or a pharmaceutically-acceptable salt and/or solvate thereof. 
N-[4-(3-benzilpirolidin-1-il)-2-metilkinolin-6-illbenzamid, ili njihova farmaceutski prihvatljiva sol i/ili solvat.
wherein R10 is phenyl, pyridinyl, pyridazinyl or pyrimidinyl, wherein each phenyl, pyridinyl, pyridazinyl or pyrimidinyl can be substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C1-6alkyl, amino, polyhaloC1-6alkyl or C1-6alkyloxy; or 
pri čemu R10 je fenil, piridinil, piridazinil ili pirimidinil, pri čemu svaki fenil, piridinil, piridazinil ili pirimidinil mogu biti supstituirani s jednim ili dva supstituenta svakim neovisno odabranim od halo, hidroksi, cijano, C1-6alkil, amino, polihaloC1-6alkil ili C1-6alkiloksi; ili
The composition according to any one of the preceding claims, characterized in that it is in the form of a coating formulation. 
Pripravak prema zahtjevu 17, naznačen time da je predviđen u obliku otopine ili disperzije u prikladnom tekućem
A pharmaceutical formulation for use in the treatment of respiratory disease according to any of claims 10 to 13 wherein Compound (I) and Compound (II) are presented as separate compositions. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s bilo kojim od patentnih zahtjeva 10 do 13, naznačena time što se Spoj (1) i Spoj (II) daje kao odvojene pripravke.
The compound according to any one of claims 1 to 5, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R2a is hydrogen or lower alkyl optionally substituted by substituent group C (substituent group C is same as that of claim 1). 
Spoj prema bilo kojem od zahtjeva 1 do 5, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R* je vodik ili niži alkil prema potrebi supstituiran sa supstituentskom skupinom €, (gdje supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 1).
An isolated nucleic acid molecule encoding at least one isolated IL-23p19 antibody according to any of claims 1-7 and 10-14. 
Izolirana molekula nukleinske kiseline: kodira najmanje jedno izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1 ili patentnom zahtjevu 2;(b) sadrži najmanje jednu od:
at least one bulking agent wherein the at least one bulking agent comprises dextran, maltodextrin, polyvinylpyrrolidone, hydroxyethyl starch, or combinations thereof or 
(b) najmanje jedno punilo pri čemu to najmanje jedno punilo sadrži dekstran, maltodekstrin, polivinilpirolidon, hidroksietil škrob ili njihove kombinacije ili
The reaction is conveniently carried out in a suitable solvent, such as an aprotic solvent, e.g. tetrahydrofuran in the presence of a suitable catalyst, for example a metal hydride. 
Reakciju se pogodno provodi u pogodnom otapalu, poput neprotonskog otapala, primjerice tetrahidrofurana, u prisutnosti pogodnog katalizatora, primjerice metalnog hidrida.
A transport unit according to any one of the previous claims, wherein the lower of the two parts of each foot extents at least 50 mm, preferably at least 100 mm, shorter than the upper part towards the closer of the side surfaces. 
Transportna jednica sukladno bilo kojem od prethodnih zahtjeva, pri čemu niži (8) od dva dijela (7, 8) svake noge (3, 4) prelazi barem 50 mm, poželjno najmanje 100 mm, kraće od gornjeg dijela (7) prema bližoj od bočnih površina.
Use according to any of the preceding items, wherein the galenic formulation is in the form of a tampon, vagitorium, vaginal aerosol, vaginal cup, vaginal gel, vaginal insert, vaginal patch, vaginal ring, vaginal sponge, vaginal suppository, vaginal cream, vaginal emulsion, vaginal foam, vaginal lotion, vaginal ointment, vaginal powder, vaginal shampoo, vaginal solution, vaginal spray, vaginal suspension, vaginal tablet, vaginal rod, vaginal shaum, vaginal disc, semipermeable packaging and any combination thereof. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku u obliku tampona, vagitorija, vaginalnog aerosola, vaginalne šalice, vaginalnog gela, vaginalnog inserta, vaginalnog flastera, vaginalnog prstena, vaginalne spužve, vaginalnog čepića, vaginalne kreme, vaginalne emulzije, vaginalne pjene, vaginalnog losiona, vaginalne pomasti, vaginalnog pudra; vaginalnog šampona, vaginalne otopine, vaginalnog spreja, vaginalne suspenzije, vaginalne tablete, vaginalnog štapića, vaginalnog šauma, vaginalnog diska, semipropusnog materijala ili bilo koje kombinacije istih.
Formula 38 was then converted to Formula 39 according to the following reaction: Formula 38 (41.37g, 52.5mmol) was dissolved in DCM (500mL) at room temperature. 
Mola: 4048.44 Formula 35 Formula 38 (41.37 g, 52,5 mmol) je bila otopljena u DCM (500 mL) na sobnoj temperaturi.
The method of claim 16, wherein the reaction occurs in a first stage and a second stage, wherein during the first stage the plurality of particulates are reacted with the at least one superhydrophobic silane, and wherein during the second stage the plurality of particulates are reacted with the at least one coupling agent. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time, da se reakcija odvija u prvom koraku i u drugom koraku, pri čemu u prvom koraku mnoštvo reagira s barem jedan superhidrofobnim silanom, i pri čemu u drugom koraku više čestica reagira s najmanje jednim sredstvom za spajanje.
Use of claim 27, wherein the dermal pathology is psoriasis. 
Uporaba prema patentnom zahtjevu 27, naznačena time što, dermalna patologija je psorijaza.
CLAUSES An anti-parasitic pour-on composition characterised by the presence of a delivery system comprising at least 20% (v/v) of one or more alcohols, and an effective amount of a salicylanilide anti-parasitic compound. 
Antiparazitna smjesa za polijevanje koja sadrži učinkovitu količinu salicilanilidnog anti-parazitnog spoja, naznačena prisutnošću transdermalnog sustava primjene koji sadrži barem 20% (v/v) jednog ili više od C;-C5 monohidro alkilnih alkohola.
(2A) preparing a tube body (1) fittingly with a roundness of a ball; 
(2A) pripremanje tijela (1) balona kako bi točno pasalo s okruglim oblikom lopte;